ExodusPoint Capital Management’s Akebia Therapeutics AKBA Stock Holding History

ExodusPoint Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-289,528	Closed	-$1.05M	–	1489
2025 Q2	$1.05M	Buy	+289,528	New	+$796K	0.01%	947
2024 Q4	–	Sell	-133,934	Closed	-$177K	–	1464
2024 Q3	$177K	Buy	+133,934	New	+$179K	﹤0.01%	1469
2024 Q2	–	Sell	-137,742	Closed	-$252K	–	1484
2024 Q1	$252K	Sell	137,742 -105,232	-43%	-$168K	﹤0.01%	1300
2023 Q4	$301K	Buy	+242,974	New	+$248K	﹤0.01%	1180
2022 Q2	–	Sell	-224,537	Closed	-$161K	–	1896
2022 Q1	$161K	Buy	224,537 +64,033	+40%	+$137K	﹤0.01%	1947
2021 Q4	$363K	Buy	160,504 +5,164	+3%	+$14.1K	﹤0.01%	1578
2021 Q3	$447K	Sell	155,340 -38,983	-20%	-$111K	0.01%	1458
2021 Q2	$736K	Buy	194,323 +109,671	+130%	+$369K	0.01%	1162
2021 Q1	$287K	Buy	84,652 +66,526	+367%	+$240K	﹤0.01%	1707
2020 Q4	$51K	Buy	+18,126	New	+$52.9K	﹤0.01%	1872

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

ExodusPoint Capital Management's AKBA Position: Q3 2025 in Review

ExodusPoint Capital Management sold out of Akebia Therapeutics (AKBA) in Q3 2025, closing a stake of 289,528 shares — an estimated $1.05M sold.

ExodusPoint Capital Management first reported a position in AKBA in Q4 2020 and held it in 10 quarters. The position peaked at $1.05M in Q2 2025. 177 funds tracked by Wall St. Rank hold AKBA as of Q3 2025.

ExodusPoint Capital Management reported no remaining Akebia Therapeutics position as of Q3 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 289,528 Akebia Therapeutics shares in Q3 2025, an estimated $1.05M.
ExodusPoint Capital Management first reported a position in Akebia Therapeutics in Q4 2020 and held it in 10 quarters.
ExodusPoint Capital Management's Akebia Therapeutics position peaked at $1.05M in Q2 2025.
177 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.